<DOC>
	<DOCNO>NCT00336947</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , S-1 tegafur-uracil , work different way stop growth tumor cell , either kill cell stop divide . Giving S-1 tegafur-uracil surgery , chemotherapy , biological therapy , and/or radiation therapy may kill remain tumor cell . It yet know whether S-1 effective tegafur-uracil treat head neck cancer . PURPOSE : This randomized phase III trial study S-1 see well work compare tegafur-uracil treating patient previously treat stage III stage IV head neck cancer .</brief_summary>
	<brief_title>S-1 Tegafur-Uracil Treating Patients With Previously Treated Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival rate patient definitively treated stage III IV squamous cell carcinoma head neck treat adjuvant chemotherapy comprise S-1 vs tegafur-uracil ( UFT ) . OUTLINE : This randomize , control , multicenter study . Patients stratify accord primary site , disease stage , type prior definitive treatment , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral S-1 daily day 1-14 . Courses repeat every 21 day 1 year absence disease progression unacceptable toxicity . - Arm II : Patients receive oral tegafur-uracil ( UFT ) daily day 1-21 . Courses repeat every 21 day 1 year absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 500 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma head neck ( SCCHN ) Stage III IV disease Primary tumor mesopharynx , hypopharynx , larynx ( except T3 N0 tumor glottis ) , oral cavity , maxillary sinus Completed definitive treatment SCCHN within past 3 month , include following : Surgery Chemotherapy Biologic therapy Radiotherapy ( e.g. , radiotherapy combination chemotherapy pre postoperative radiotherapy ) Any treatment No clinical evidence locoregional tumor distant metastasis within 3 month completion definitive treatment PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,500/mm^3 AND ≤ 12,000/mm^3 Neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL AST ALT &lt; 100 IU/L Bilirubin &lt; 1.5 mg/dL Creatinine &lt; 1.2 mg/dL No uncontrolled cardiovascular disease No interstitial pneumonia pulmonary fibrosis Must sufficient oral intake PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent biologic therapy , radiotherapy , chemotherapy , therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>